T1	p 109 192	patients with primary Raynaud 's phenomenon in South Korea ; Korean Raynaud study (
T2	p 356 385	primary Raynaud 's phenomenon
T3	p 396 403	Korea .
T4	p 415 441	were screened and assigned
T5	p 484 487	N )
T6	p 740 761	Ninety-three subjects
T7	p 1114 1131	Korean patients .
T8	p 1171 1182	RP patients
T9	i 44 54	nifedipine
T10	i 78 99	Ginkgo biloba extract
T11	i 177 184	Raynaud
T12	i 256 276	nifedipine sustained
T13	i 287 300	nifedipine SR
T14	i 317 338	Ginkgo biloba extract
T15	i 456 469	nifedipine SR
T16	i 476 477	(
T17	i 484 487	N )
T18	i 495 524	Ginkgo biloba extract group (
T19	i 533 534	)
T20	i 1023 1036	nifedipine SR
T21	i 1061 1082	Ginkgo biloba extract
T22	o 21 40	efficacy and safety
T23	o 233 252	efficacy and safety
T24	o 277 286	release (
T25	o 372 385	's phenomenon
T26	o 677 691	RP attack rate
T27	o 908 942	No serious adverse events occurred
T28	o 956 970	adverse events